-
1
-
-
84864460325
-
Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin
-
Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012; 29(8): 2104-2114.
-
(2012)
Pharm Res
, vol.29
, Issue.8
, pp. 2104-2114
-
-
Jonassen, I.1
Havelund, S.2
Hoeg-Jensen, T.3
Steensgaard, D.B.4
Wahlund, P.O.5
Ribel, U.6
-
2
-
-
84859746575
-
Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec
-
42-LB, (abstract)
-
Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec. Diabetes 2011; 60 Suppl 1A: 42-LB (abstract).
-
(2011)
Diabetes
, vol.60
, Issue.SUPPL. 1A
-
-
Kurtzhals, P.1
Heise, T.2
Strauss, H.M.3
-
3
-
-
34948861041
-
Refining basal insulin therapy: What have we learned in the age of analogues?
-
Devries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev. 2007; 23(6): 441-454.
-
(2007)
Diabetes Metab Res Rev
, vol.23
, Issue.6
, pp. 441-454
-
-
Devries, J.H.1
Nattrass, M.2
Pieber, T.R.3
-
4
-
-
34547908855
-
Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies
-
Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007; 9(5): 648-659.
-
(2007)
Diabetes Obes Metab
, vol.9
, Issue.5
, pp. 648-659
-
-
Heise, T.1
Pieber, T.R.2
-
5
-
-
84883510524
-
β-Cell differentiation and regeneration in type 1 diabetes
-
Ding L, Gysemans C, Mathieu C. β-Cell differentiation and regeneration in type 1 diabetes. Diabetes Obes Metab. 2013; 15 Suppl 3: 98-104.
-
(2013)
Diabetes Obes Metab
, vol.15
, Issue.SUPPL. 3
, pp. 98-104
-
-
Ding, L.1
Gysemans, C.2
Mathieu, C.3
-
6
-
-
0013913701
-
Application of newer concepts in diabetes
-
Fineberg SK. Application of newer concepts in diabetes. J Am Geriatr Soc. 1966; 14(5): 463-471.
-
(1966)
J Am Geriatr Soc
, vol.14
, Issue.5
, pp. 463-471
-
-
Fineberg, S.K.1
-
7
-
-
84899758364
-
-
Accessed January 26, National Diabetes Information Clearinghouse (NDIC), 2008, NIH Publication No 09-3873. Bethesda, MD: NDIC; Available from
-
National Diabetes Information Clearinghouse (NDIC). Diabetes overview [web page on the Internet]. NIH Publication No 09-3873. Bethesda, MD: NDIC; 2008. Available from: http://diabetes. niddk. nih. gov/dm/pubs/overview/. Accessed January 26, 2014.
-
(2014)
Diabetes overview [web page on the Internet]
-
-
-
8
-
-
84871995815
-
Standards of medical care in diabetes-2013
-
American Diabetes Association
-
American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013; 36 Suppl 1: S11-S66.
-
(2013)
Diabetes Care
, vol.36
, Issue.SUPPL. 1
-
-
-
9
-
-
0023916553
-
Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus
-
Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988; 318(19): 1231-1239.
-
(1988)
N Engl J Med
, vol.318
, Issue.19
, pp. 1231-1239
-
-
Polonsky, K.S.1
Given, B.D.2
Hirsch, L.J.3
-
10
-
-
84866268783
-
Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
-
American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD)
-
Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6): 1364-1379.
-
(2012)
Diabetes Care
, vol.35
, Issue.6
, pp. 1364-1379
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
11
-
-
70350328268
-
Restaging insulin therapy for patients with type 2 diabetes
-
Garber AJ. Restaging insulin therapy for patients with type 2 diabetes. Diabetes Obes Metab. 2009; 11 Suppl 5: 1-5.
-
(2009)
Diabetes Obes Metab
, vol.11
, Issue.SUPPL. 5
, pp. 1-5
-
-
Garber, A.J.1
-
12
-
-
2542576404
-
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes
-
Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004; 53(6): 1614-1620.
-
(2004)
Diabetes
, vol.53
, Issue.6
, pp. 1614-1620
-
-
Heise, T.1
Nosek, L.2
Rønn, B.B.3
-
13
-
-
80054071230
-
The future of basal insulin supplementation
-
Simon AC, DeVries JH. The future of basal insulin supplementation. Diabetes Technol Ther. 2011; 13 Suppl 1: S103-S108.
-
(2011)
Diabetes Technol Ther
, vol.13
, Issue.SUPPL. 1
-
-
Simon, A.C.1
DeVries, J.H.2
-
14
-
-
84859842346
-
Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study
-
Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012; 29(5): 682-689.
-
(2012)
Diabet Med
, vol.29
, Issue.5
, pp. 682-689
-
-
Peyrot, M.1
Barnett, A.H.2
Meneghini, L.F.3
Schumm-Draeger, P.M.4
-
15
-
-
0017127682
-
The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man
-
Garber AJ, Cryer PE, Santiago JV, Haymond MW, Pagliara AS, Kipnis DM. The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man. J Clin Invest. 1976; 58(1): 7-15.
-
(1976)
J Clin Invest
, vol.58
, Issue.1
, pp. 7-15
-
-
Garber, A.J.1
Cryer, P.E.2
Santiago, J.V.3
Haymond, M.W.4
Pagliara, A.S.5
Kipnis, D.M.6
-
17
-
-
0036020278
-
Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II diabetes
-
Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia. 2002; 45(7): 937-948.
-
(2002)
Diabetologia
, vol.45
, Issue.7
, pp. 937-948
-
-
Cryer, P.E.1
-
18
-
-
0036314189
-
Hypoglycemia-associated autonomic failure in advanced type 2 diabetes
-
Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 2002; 51(3): 724-733.
-
(2002)
Diabetes
, vol.51
, Issue.3
, pp. 724-733
-
-
Segel, S.A.1
Paramore, D.S.2
Cryer, P.E.3
-
20
-
-
0001909792
-
Impaired hypoglycaemia awareness
-
In: Frier BM, Fisher M, editors., Chichester: Wiley
-
Frier BM, Fisher M. Impaired hypoglycaemia awareness. In: Frier BM, Fisher M, editors. Hypoglycaemia in Clinical Diabetes. Chichester: Wiley; 1999: 111-146.
-
(1999)
Hypoglycaemia in Clinical Diabetes
, pp. 111-146
-
-
Frier, B.M.1
Fisher, M.2
-
21
-
-
84881416448
-
Severe hypoglycaemia and cardiovascular disease: Systematic review and meta-analysis with bias analysis
-
Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013; 347: f4533.
-
(2013)
BMJ
, vol.347
-
-
Goto, A.1
Arah, O.A.2
Goto, M.3
Terauchi, Y.4
Noda, M.5
-
22
-
-
33748366186
-
Hypoglycemia in type 1 and type 2 diabetes: Physiology, pathophysiology, and management
-
Briscoe VJ, Davis SN. Hypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology, and management. Clin Diabetes. 2006; 24(3): 115-121.
-
(2006)
Clin Diabetes
, vol.24
, Issue.3
, pp. 115-121
-
-
Briscoe, V.J.1
Davis, S.N.2
-
23
-
-
18144388647
-
Defining and reporting hypoglycemia in diabetes: A report from the American Diabetes Association Workgroup on Hypoglycemia
-
Workgroup on Hypoglycemia, American Diabetes Association
-
Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005; 28(5): 1245-1249.
-
(2005)
Diabetes Care
, vol.28
, Issue.5
, pp. 1245-1249
-
-
-
24
-
-
20444408424
-
Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: A population-based study
-
DARTS/MEMO Collaboration
-
Donnelly LA, Morris AD, Frier BM, et al; DARTS/MEMO Collaboration. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med. 2005; 22(6): 749-755.
-
(2005)
Diabet Med
, vol.22
, Issue.6
, pp. 749-755
-
-
Donnelly, L.A.1
Morris, A.D.2
Frier, B.M.3
-
25
-
-
33646678474
-
Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management
-
Leiter LA, Yale JF, Chiasson JL, Harris SB, Kleinstiver P, Saurio L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes. 2005; 29(3): 186-192.
-
(2005)
Can J Diabetes
, vol.29
, Issue.3
, pp. 186-192
-
-
Leiter, L.A.1
Yale, J.F.2
Chiasson, J.L.3
Harris, S.B.4
Kleinstiver, P.5
Saurio, L.6
-
26
-
-
84894563962
-
GAPP2™: Global survey finds three quarters of patients experience hypoglycaemia on insulin analogue causing dose irregularities and increased blood glucose monitoring
-
Tahrani A, Barnett A, Brod M, Rana M, Peyrot M. GAPP2™: Global survey finds three quarters of patients experience hypoglycaemia on insulin analogue causing dose irregularities and increased blood glucose monitoring. Diabetologia. 2012; 55 Suppl 1: S98-S99.
-
(2012)
Diabetologia
, vol.55
, Issue.SUPPL. 1
-
-
Tahrani, A.1
Barnett, A.2
Brod, M.3
Rana, M.4
Peyrot, M.5
-
27
-
-
80054749694
-
The incidence and costs of hypoglycemia in type 2 diabetes
-
Quilliam BJ, Simeone JC, Ozbay AB, Kogut SJ. The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care. 2011; 17(10): 673-680.
-
(2011)
Am J Manag Care
, vol.17
, Issue.10
, pp. 673-680
-
-
Quilliam, B.J.1
Simeone, J.C.2
Ozbay, A.B.3
Kogut, S.J.4
-
28
-
-
1042302782
-
Insulin administration
-
American Diabetes Association
-
American Diabetes Association. Insulin administration. Diabetes Care. 2004; 27(90001): 106S-107S.
-
(2004)
Diabetes Care
, vol.27
-
-
-
29
-
-
84862501914
-
Management of diabetes mellitus: Is the pump mightier than the pen?
-
Pickup JC. Management of diabetes mellitus: is the pump mightier than the pen? Nat Rev Endocrinol. 2012; 8(7): 425-433.
-
(2012)
Nat Rev Endocrinol
, vol.8
, Issue.7
, pp. 425-433
-
-
Pickup, J.C.1
-
30
-
-
84874126435
-
Differential associations between depressive symptoms and glycaemic control in outpatients with diabetes
-
Bot M, Pouwer F, de Jonge P, Tack CJ, Geelhoed-Duijvestijn PH, Snoek FJ. Differential associations between depressive symptoms and glycaemic control in outpatients with diabetes. Diabet Med. 2013; 30(3): e115-e122.
-
(2013)
Diabet Med
, vol.30
, Issue.3
-
-
Bot, M.1
Pouwer, F.2
de Jonge, P.3
Tack, C.J.4
Geelhoed-Duijvestijn, P.H.5
Snoek, F.J.6
-
31
-
-
84867338418
-
Epidemiology of depression and diabetes: A systematic review
-
Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. J Affect Disord. 2012; 142 Suppl: S8-S21.
-
(2012)
J Affect Disord
, vol.142
, Issue.SUPPL.
-
-
Roy, T.1
Lloyd, C.E.2
-
32
-
-
84878148848
-
Association of depression with increased risk of severe hypoglycemic episodes in patients with diabetes
-
Katon WJ, Young BA, Russo J, et al. Association of depression with increased risk of severe hypoglycemic episodes in patients with diabetes. Ann Fam Med. 2013; 11(3): 245-250.
-
(2013)
Ann Fam Med
, vol.11
, Issue.3
, pp. 245-250
-
-
Katon, W.J.1
Young, B.A.2
Russo, J.3
-
33
-
-
84879643475
-
Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus
-
Health ABC Study
-
Yaffe K, Falvey CM, Hamilton N, et al; Health ABC Study. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013; 173(14): 1300-1306.
-
(2013)
JAMA Intern Med
, vol.173
, Issue.14
, pp. 1300-1306
-
-
Yaffe, K.1
Falvey, C.M.2
Hamilton, N.3
-
34
-
-
77952766075
-
Determinants of severe hypoglycemia complicating type 2 diabetes: The Fremantle diabetes study
-
Davis TM, Brown SG, Jacobs IG, Bulsara M, Bruce DG, Davis WA. Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab. 2010; 95(5): 2240-2247.
-
(2010)
J Clin Endocrinol Metab
, vol.95
, Issue.5
, pp. 2240-2247
-
-
Davis, T.M.1
Brown, S.G.2
Jacobs, I.G.3
Bulsara, M.4
Bruce, D.G.5
Davis, W.A.6
-
35
-
-
40049106685
-
Hypoglycaemia in Type 2 diabetes
-
Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet Med. 2008; 25(3): 245-254.
-
(2008)
Diabet Med
, vol.25
, Issue.3
, pp. 245-254
-
-
Amiel, S.A.1
Dixon, T.2
Mann, R.3
Jameson, K.4
-
36
-
-
26244459804
-
Pharmacokinetic and glucodynamic variability: Assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique
-
Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia. 2005; 48(10): 1988-1995.
-
(2005)
Diabetologia
, vol.48
, Issue.10
, pp. 1988-1995
-
-
Scholtz, H.E.1
Pretorius, S.G.2
Wessels, D.H.3
Becker, R.H.4
-
37
-
-
84899708585
-
Will the next generation of basal insulins offer clinical advantages?
-
Epub October 4
-
Garber AJ. Will the next generation of basal insulins offer clinical advantages? Diabetes Obes Metab. Epub October 4, 2013.
-
(2013)
Diabetes Obes Metab
-
-
Garber, A.J.1
-
38
-
-
84859921058
-
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): A phase 3, randomised, open-label, treat-to-target non-inferiority trial
-
NN1250-3582 (BEGIN BB T2D) Trial Investigators
-
Garber AJ, King AB, Del Prato S, et al; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012; 379(9825): 1498-1507.
-
(2012)
Lancet
, vol.379
, Issue.9825
, pp. 1498-1507
-
-
Garber, A.J.1
King, A.B.2
Del Prato, S.3
-
39
-
-
84859896417
-
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): A phase 3, randomised, open-label, treat-to-target non-inferiority trial
-
BEGIN Basal-Bolus Type 1 Trial Investigators
-
Heller S, Buse J, Fisher M, et al; BEGIN Basal-Bolus Type 1 Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012; 379(9825): 1489-1497.
-
(2012)
Lancet
, vol.379
, Issue.9825
, pp. 1489-1497
-
-
Heller, S.1
Buse, J.2
Fisher, M.3
-
40
-
-
84871937855
-
Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: A pre-planned meta-analysis of phase 3 trials
-
Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013; 15(2): 175-184.
-
(2013)
Diabetes Obes Metab
, vol.15
, Issue.2
, pp. 175-184
-
-
Ratner, R.E.1
Gough, S.C.2
Mathieu, C.3
-
41
-
-
84869842163
-
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
-
NN1250-3579 (BEGIN Once Long) Trial Investigators
-
Zinman B, Philis-Tsimikas A, Cariou B, et al; NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012; 35(12): 2464-2471.
-
(2012)
Diabetes Care
, vol.35
, Issue.12
, pp. 2464-2471
-
-
Zinman, B.1
Philis-Tsimikas, A.2
Cariou, B.3
-
42
-
-
84865972844
-
Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes
-
Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012; 14(10): 944-950.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.10
, pp. 944-950
-
-
Heise, T.1
Nosek, L.2
Bøttcher, S.G.3
Hastrup, H.4
Haahr, H.5
-
43
-
-
84859883969
-
Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine
-
37-LB, (abstract)
-
Heise T, Hövelmann U, Nosek L, Bøttcher S, Granhall C, Haahr H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetes. 2011; 60 Suppl 1A: 37-LB (abstract).
-
(2011)
Diabetes
, vol.60
, Issue.SUPPL. 1A
-
-
Heise, T.1
Hövelmann, U.2
Nosek, L.3
Bøttcher, S.4
Granhall, C.5
Haahr, H.6
-
44
-
-
84885871790
-
Steady state is reached within two to three days of once-daily administration of ultra-long-acting insulin degludec
-
(abstract)
-
Heise T, Nosek L, Coester HV, et al. Steady state is reached within two to three days of once-daily administration of ultra-long-acting insulin degludec. Diabetes 2012; 61 Suppl 1: A259 (abstract).
-
(2012)
Diabetes
, vol.61
, Issue.SUPPL. 1
-
-
Heise, T.1
Nosek, L.2
Coester, H.V.3
-
45
-
-
84864375931
-
Insulin degludec: Four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
-
Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012; 14(9): 859-864.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.9
, pp. 859-864
-
-
Heise, T.1
Hermanski, L.2
Nosek, L.3
Feldman, A.4
Rasmussen, S.5
Haahr, H.6
-
46
-
-
84899030576
-
Insulin degludec: Pharmacokinetic properties in subjects with hepatic impairment
-
Kupčová V, Arold G, Roepstorff C, Højbjerre M, Klim S, Haahr HL. Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. Clin Drug Investig. 2014; 34(2): 127-133.
-
(2014)
Clin Drug Investig
, vol.34
, Issue.2
, pp. 127-133
-
-
Kupčová, V.1
Arold, G.2
Roepstorff, C.3
Højbjerre, M.4
Klim, S.5
Haahr, H.L.6
-
47
-
-
84893286934
-
Insulin degludec: Pharmacokinetics in patients with renal impairment
-
Kiss I, Arold G, Roepstorff C, Bøttcher SG, Klim S, Haahr H. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet. 2013; 53(2): 175-183.
-
(2013)
Clin Pharmacokinet
, vol.53
, Issue.2
, pp. 175-183
-
-
Kiss, I.1
Arold, G.2
Roepstorff, C.3
Bøttcher, S.G.4
Klim, S.5
Haahr, H.6
-
48
-
-
84892925546
-
Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus
-
Korsatko S, Deller S, Mader JK, et al. Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus. Drugs Aging. 2013; 31(1): 47-53.
-
(2013)
Drugs Aging
, vol.31
, Issue.1
, pp. 47-53
-
-
Korsatko, S.1
Deller, S.2
Mader, J.K.3
-
49
-
-
84865855360
-
Ultra-long pharmacokinetic properties of insulin degludec in adults with type 1 diabetes is preserved in children and adolescents after single-dose administration
-
Danne T, Bieter T, Blaesig S, et al. Ultra-long pharmacokinetic properties of insulin degludec in adults with type 1 diabetes is preserved in children and adolescents after single-dose administration. Diabetologia. 2011; 54(Suppl 1): S425.
-
(2011)
Diabetologia
, vol.54
, Issue.SUPPL. 1
-
-
Danne, T.1
Bieter, T.2
Blaesig, S.3
-
50
-
-
11844250564
-
Insulin analogues
-
Hirsch IB. Insulin analogues. N Engl J Med. 2005; 352(2): 174-183.
-
(2005)
N Engl J Med
, vol.352
, Issue.2
, pp. 174-183
-
-
Hirsch, I.B.1
-
51
-
-
0037737732
-
Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review
-
DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003; 289(17): 2254-2264.
-
(2003)
JAMA
, vol.289
, Issue.17
, pp. 2254-2264
-
-
DeWitt, D.E.1
Hirsch, I.B.2
-
52
-
-
84892724602
-
Insulin stacking versus therapeutic accumulation: Understanding the differences
-
Heise T, Meneghini LF. Insulin stacking versus therapeutic accumulation: understanding the differences. Endocr Pract. 2013; 20(1): 75-83.
-
(2013)
Endocr Pract
, vol.20
, Issue.1
, pp. 75-83
-
-
Heise, T.1
Meneghini, L.F.2
-
53
-
-
84875444482
-
The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
-
NN1250-3668 (BEGIN FLEX) Trial Investigators
-
Meneghini L, Atkin SL, Gough SC, et al; NN1250-3668 (BEGIN FLEX) Trial Investigators. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013; 36(4): 858-864.
-
(2013)
Diabetes Care
, vol.36
, Issue.4
, pp. 858-864
-
-
Meneghini, L.1
Atkin, S.L.2
Gough, S.C.3
-
54
-
-
84874858316
-
Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): A 26-week randomized, treat-to-target trial with a 26-week extension
-
NN1250-3770 (BEGIN: Flex T1) Trial Investigators
-
Mathieu C, Hollander P, Miranda-Palma B, et al; NN1250-3770 (BEGIN: Flex T1) Trial Investigators. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013; 98(3): 1154-1162.
-
(2013)
J Clin Endocrinol Metab
, vol.98
, Issue.3
, pp. 1154-1162
-
-
Mathieu, C.1
Hollander, P.2
Miranda-Palma, B.3
-
55
-
-
84888440169
-
Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial
-
Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig. 2013; 4(6): 605-612.
-
(2013)
J Diabetes Investig
, vol.4
, Issue.6
, pp. 605-612
-
-
Onishi, Y.1
Iwamoto, Y.2
Yoo, S.J.3
Clauson, P.4
Tamer, S.C.5
Park, S.6
-
56
-
-
84889648892
-
Low-volume insulin degludec 200 units/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial
-
Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-volume insulin degludec 200 units/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013; 36(9): 2536-2542.
-
(2013)
Diabetes Care
, vol.36
, Issue.9
, pp. 2536-2542
-
-
Gough, S.C.1
Bhargava, A.2
Jain, R.3
Mersebach, H.4
Rasmussen, S.5
Bergenstal, R.M.6
-
57
-
-
84899761571
-
-
Novo Nordisk, Accessed January 26, gov [website on the Internet], In: ClinicalTrials, Bethseda, MD: US National Library of Medicine; 2008 [updated September 17, 2013]. Available from
-
Novo Nordisk. Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2008 [updated September 17, 2013]. Available from: http://clinicaltrials. gov/show/NCT00982644. NLM identifier: NCT00982644. Accessed January 26, 2014.
-
(2014)
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)
-
-
-
58
-
-
84899759954
-
-
Accessed January 26, Novo Nordisk, gov [website on the Internet], In: ClinicalTrials, Bethseda, MD: US National Library of Medicine; 2009 [updated November 14, 2013]. Available from
-
Novo Nordisk. Comparison of NN1250 with insulin glargine plus insulin aspart with/without metformin and with/without pioglitazone in type 2 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2009 [updated November 14, 2013]. Available from: http://clinicaltrials. gov/ct2/show/NCT00972283. NLM identifier: NCT00972283. Accessed January 26, 2014.
-
(2014)
Comparison of NN1250 with insulin glargine plus insulin aspart with/without metformin and with/without pioglitazone in type 2 diabetes (BEGIN™)
-
-
-
59
-
-
84899756910
-
-
Accessed January 26, gov [website on the Internet], Novo Nordisk, In: ClinicalTrials, Bethseda, MD: US National Library of Medicine; 2009 [updated November 28, 2013]. Available from
-
Novo Nordisk. Comparison of NN1250 plus insulin aspart with insulin glargine plus insulin aspart in type 1 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2009 [updated November 28, 2013]. Available from: http://clinicaltrials. gov/show/NCT00982228. NLM identifier: NCT00982228. Accessed January 26, 2014.
-
(2014)
Comparison of NN1250 plus insulin aspart with insulin glargine plus insulin aspart in type 1 diabetes (BEGIN™)
-
-
-
60
-
-
84899761571
-
-
Novo Nordisk, gov [website on the Internet], Accessed January 26, In: ClinicalTrials, Bethseda, MD: US National Library of Medicine; 2009 [updated November 26, 2013]. Available from
-
Novo Nordisk. Comparison of NN1250 with insulin glargine in type 2 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2009 [updated November 26, 2013]. Available from: http://clinicaltrials. gov/show/NCT01006291. NLM identifier: NCT01006291. Accessed January 26, 2014.
-
(2014)
Comparison of NN1250 with insulin glargine in type 2 diabetes (BEGIN™)
-
-
-
61
-
-
84899721060
-
-
Novo Nordisk, gov [website on the Internet], Accessed January 26, In: ClinicalTrials, Bethseda, MD: US National Library of Medicine; 2010 [updated November 20, 2013]. Available from
-
Novo Nordisk. Comparison of NN1250 with insulin glargine in type 1 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated November 20, 2013]. Available from: http://clinicaltrials. gov/show/NCT01079234. NLM identifier: NCT01079234. Accessed January 26, 2014.
-
(2014)
Comparison of NN1250 with insulin glargine in type 1 diabetes (BEGIN™)
-
-
-
62
-
-
84899761571
-
-
Novo Nordisk, gov [website on the Internet], Accessed January 26, In: ClinicalTrials, Bethseda, MD: US National Library of Medicine; 2010 [updated November 21, 2013]. Available from
-
Novo Nordisk. Comparison of NN1250 versus insulin glargine in subjects with type 2 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated November 21, 2013]. Available from: http://clinicaltrials. gov/show/NCT01059799. NLM identifier: NCT01059799. Accessed January 26, 2014.
-
(2014)
Comparison of NN1250 versus insulin glargine in subjects with type 2 diabetes (BEGIN™)
-
-
-
63
-
-
84899761571
-
-
Novo Nordisk, gov [website on the Internet], Accessed January 26, In: ClinicalTrials, Bethseda, MD: US National Library of Medicine; 2010 [updated November 26, 2013]. Available from
-
Novo Nordisk. Comparison of NN1250 with insulin glargine in subjects with type 2 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated November 26, 2013]. Available from: http://clinicaltrials. gov/show/NCT01068665. NLM identifier: NCT01068665. Accessed January 26, 2014.
-
(2014)
Comparison of NN1250 with insulin glargine in subjects with type 2 diabetes (BEGIN™)
-
-
-
64
-
-
84899747668
-
Duration and impact of hypoglycemic events with insulin degludec and insulin glargine-a meta-analysis
-
Harris SB, Vora J, Christensen T, Kapur R, Brod M. Duration and impact of hypoglycemic events with insulin degludec and insulin glargine-a meta-analysis. Can J Diabetes. 2013; 37(Suppl 4): S54.
-
(2013)
Can J Diabetes
, vol.37
, Issue.SUPPL. 4
-
-
Harris, S.B.1
Vora, J.2
Christensen, T.3
Kapur, R.4
Brod, M.5
-
65
-
-
84899725387
-
-
Tresiba (degludec) [summary of product characteristics], Accessed January 26, Available from
-
Tresiba (degludec) [summary of product characteristics]. Bagsværd: Novo Nordisk; 2013. Available from: http://ec. europa. eu/health/documents/community-register/2013/20130121124987/anx_124987_en. pdf. Accessed January 26, 2014.
-
(2014)
Bagsværd: Novo Nordisk; 2013
-
-
-
66
-
-
84884502135
-
Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: Results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials
-
NN1250-3724 (BEGIN: EASY AM), NN1250-3718 (BEGIN: EASY PM) Trial Investigators
-
Zinman B, DeVries JH, Bode B, et al; NN1250-3724 (BEGIN: EASY AM), NN1250-3718 (BEGIN: EASY PM) Trial Investigators. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabetes Endocrinol. 2013; 1(2): 123-131.
-
(2013)
Lancet Diabetes Endocrinol
, vol.1
, Issue.2
, pp. 123-131
-
-
Zinman, B.1
DeVries, J.H.2
Bode, B.3
-
67
-
-
84856591819
-
Improving safety of insulin administration: A pilot audit of hospital staff knowledge
-
Sharpe L. Improving safety of insulin administration: A pilot audit of hospital staff knowledge. J Diabetes Nurs. 2012; 16(1): 8-16.
-
(2012)
J Diabetes Nurs
, vol.16
, Issue.1
, pp. 8-16
-
-
Sharpe, L.1
-
68
-
-
84879814052
-
A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec
-
Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig. 2013; 33(7): 515-521.
-
(2013)
Clin Drug Investig
, vol.33
, Issue.7
, pp. 515-521
-
-
Korsatko, S.1
Deller, S.2
Koehler, G.3
-
69
-
-
3042823834
-
Hypoglycaemia in elderly patients with diabetes mellitus: Causes and strategies for prevention
-
Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging. 2004; 21(8): 511-530.
-
(2004)
Drugs Aging
, vol.21
, Issue.8
, pp. 511-530
-
-
Chelliah, A.1
Burge, M.R.2
-
70
-
-
0030852089
-
Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas
-
Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997; 157(15): 1681-1686.
-
(1997)
Arch Intern Med
, vol.157
, Issue.15
, pp. 1681-1686
-
-
Shorr, R.I.1
Ray, W.A.2
Daugherty, J.R.3
Griffin, M.R.4
-
71
-
-
84892924090
-
Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: A meta-analysis of phase IIIa trials
-
Sorli C, Warren M, Oyer D, Mersebach H, Johansen T, Gough SC. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials. Drugs Aging. 2013; 30(12): 1009-1018.
-
(2013)
Drugs Aging
, vol.30
, Issue.12
, pp. 1009-1018
-
-
Sorli, C.1
Warren, M.2
Oyer, D.3
Mersebach, H.4
Johansen, T.5
Gough, S.C.6
|